EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec

Debra D Pittman, Charles Carrieri, Holly Soares, John McKay, Charles Y Tan, John Z Liang, Swapnil Rakhe, Jean-Claude Marshall, John E Murphy, Puneet Gaitonde, Jeremy Rupon

Thrombosis and Haemostasis · 01.10.2024 · 124 (10) · 912-921

DOI: 10.1055/s-0044-1787734 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.10.2024. Verfasst von Debra D Pittman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B, Genetic Therapy, Blood Coagulation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fidanacogene elaparvovec, an adeno-associated virus-based gene therapy vector expressing the high-activity factor IX (FIX) variant FIX-R338L, is in development for hemophilia B. One-stage clotting (OS) assays and chromogenic substrate (CS) assays are commonly used to measure FIX-R338L variant activity. Data from ongoing trials suggest FIX activity varies between different OS and CS assays. Material and Methods To better understand FIX-R338L activity in clinical samples, an international multisite field study was conducted across a central laboratory and 18 local laboratories, using standard protocols, reagents, and instrumentation, with individual participant samples from a phase 1/2a study of fidanacogene elaparvovec.

Results

Unlike the wild-type FIX control, FIX-R338L activity was higher with the OS silica-based assay versus OS ellagic acid–based and CS assays. Variation in FIX activity was greater at the lowest activity levels. Activated FIX (FIXa) in plasma could result in higher OS assay activity or increased thrombin generation, which could overestimate FIX activity. However, FIXa was not detected in the participant samples, indicating that it was not contributing to the OS assay differences. Since individuals on gene therapy may receive exogenous replacement FIX products, replacement products were spiked into patient plasma samples to target a therapeutic concentration. Exogenous FIX was additive to endogenous FIX-R338L, with no interference from FIX-R338L.

Conclusion

These results demonstrate FIX-R338L activity can be measured with OS and CS assays in clinical laboratories and provide insight into assay variability when measuring FIX with endogenously produced FIX-R338L. The findings may help establish best practices for measuring FIX-R338L activity (Clinicaltrials.gov identifier: NCT02484092).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXHemophilia BGenetic TherapyBlood CoagulationDependovirusHumansBlood Coagulation TestsGenetic VectorsThrombin

Substanzen

Factor IXThrombin

Autor:innen und Institutionen

  • Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States.
  • Pfizer Inc., New York, New York, United States.
  • Pfizer Inc., Groton, Connecticut, United States.
  • Pfizer Inc., Cambridge, Massachusetts, United States.
  • Pfizer Inc., Collegeville, Pennsylvania, United States.

Zitieren

APA

Pittman, D. D., Carrieri, C., Soares, H., McKay, J., Tan, C. Y., Liang, J. Z., Rakhe, S., Marshall, J. C., Murphy, J. E., Gaitonde, P., & Rupon, J. (2024). Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec. Thrombosis and Haemostasis, 124(10), 912-921. https://doi.org/10.1055/s-0044-1787734

Vancouver

Pittman DD, Carrieri C, Soares H, McKay J, Tan CY, Liang JZ, et al. Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec. Thrombosis and Haemostasis. 2024;124(10):912-921. doi:10.1055/s-0044-1787734

BibTeX
@article{Pittman2024,
  author = {Pittman, Debra D and Carrieri, Charles and Soares, Holly and McKay, John and Tan, Charles Y and Liang, John Z and Rakhe, Swapnil and Marshall, Jean-Claude and Murphy, John E and Gaitonde, Puneet and Rupon, Jeremy},
  title = {Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {10},
  pages = {912--921},
  doi = {10.1055/s-0044-1787734}
}
Kostenlos starten →